<DOC>
	<DOCNO>NCT02060487</DOCNO>
	<brief_summary>This blind study adult patient PAH evaluate relative effect sildenafil mortality administer three dos ( 80 mg , 20 mg 5 mg , three time per day [ TID ] ) . In addition , relative effect clinical worsen 6-minute walking distance ( 6MWD ) assess .</brief_summary>
	<brief_title>Effects Oral Sildenafil Mortality Adults With PAH</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Subjects ≥ 18 &lt; 75 year age follow condition : Idiopathic Primary Pulmonary Arterial Hypertension ( IPAH ) PAH secondary connective tissue disease PAH surgical repair ( least 5 year previously ) atrial septal defect ( ASD ) , ventricular septal defect ( VSD ) , patent ductus arteriosus ( PDA ) aortopulmonary window PAH diagnosis confirm right heart catheterization perform within 12 month prior randomization Functional Class IIIV ; Baseline 6MWD ≥ 50 m. Significant ( ie , &gt; 2+ ) valvular disease tricuspid regurgitation pulmonary regurgitation History cardiac arrest , respiratory arrest , hemodynamic collapse , CPR , ventricular tachycardia , ventricular fibrillation , uncontrolled atrial fibrillation History pulmonary embolism ; History chronic lung disease / restrictive lung disease ( eg , chronic obstructive pulmonary disease ( COPD ) scleroderma ) impairment lung function No prior long term treatment PDE5 inhibitor Treatment bosentan OR riociguat within 3 month randomization Current treatment nitrate nitric oxide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>pulmonary hypertension</keyword>
	<keyword>PAH</keyword>
	<keyword>sildenafil</keyword>
	<keyword>revatio</keyword>
</DOC>